Forging Hopeful Futures to Reduce Youth Violence (FHF)

August 31, 2026 updated by: Alison Culyba, University of Pittsburgh

Forging Hopeful Futures: A Racial and Gender-Justice Program to Reduce Youth Violence

This cluster-randomized community-partnered study will examine the effectiveness of a racial-, gender-, and economic-justice focused youth violence prevention program called Forging Hopeful Futures with youth ages 13-19.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Completed

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Detailed Description

This community-partnered cluster randomized trial in 16 neighborhoods impacted by structural inequities and high levels of community violence in Pittsburgh, PA and urban Washington D.C. and Maryland metro areas will evaluate effectiveness of Forging Hopeful Futures with youth ages 13-19. Forging Hopeful Futures combines economic justice content from job readiness training, racial and gender justice content from gender-transformative programming, and leadership building as a novel multi-level violence prevention intervention.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Actual)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
542

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact

The name and contact information for the person who can answer enrollment questions for a clinical study. Each location where the study is being conducted may also have a specific contact, who may be better able to answer those questions.

Study Contact Backup

Study Locations

  • United States
    • District of Columbia
      • Washington D.C., District of Columbia, United States, 20008
        • Population Council
    • Pennsylvania
      • Pittsburgh, Pennsylvania, United States, 15213
        • University of Pittsburgh

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

14 years to 19 years (Child, Adult)

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

  1. Participants must be ages 13-19 (inclusive)
  2. Participants must speak English
  3. Participants must live in the participating neighborhoods, attend schools in the participating neighborhoods, or use participating facilities
  4. Participants must be able to provide follow up contact information

Exclusion Criteria:

  1. Not ages 13 -19 (inclusive)
  2. Do not speak English
  3. Do not live in the participating neighborhoods, attend schools in the participating neighborhoods, or use participating facilities
  4. Unable to provide follow up contact information

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Prevention
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Active Comparator: Wellness Check-ins
Youth in neighborhoods randomized to the control group will receive individual wellness checks. This will occur through a strengths-based telephone conversation focused on wellness resources. Youth will be provided with tailored resources based on needs identified during the call. Youth will be offered the option for additional phone check-ins to coordinate access to community resources and connection to individualized behavioral health supports if desired.
Behavioral: Wellness Check-ins
Individual wellness checks will occur through a strengths-based telephone conversation focused on wellness resources. Youth will be provided with tailored resources based on needs identified during the call. Youth will be offered the option for additional phone check-ins to coordinate access to community resources and connection to individualized behavioral health supports if desired.
Experimental: Forging Hopeful Futures
Forging Hopeful Futures uses a group discussion format with activities that explore race, gender, class, identity, relationships, and multiple forms of violence. Forging Hopeful Futures is a 12 session curriculum for youth ages 13-19 that uses strengths-based and healing-centered approaches to critically examine structural forces that perpetuate racial and gender injustice, develop leadership skills in promoting gender equitable relationship norms, non-violent practices, and upstander skills, and enhance economic justice through job skills and employment opportunities. Through 12 sessions (3 hours/session) over a 6 to 12 week period, Forging Hopeful Futures combines racial, gender, and economic justice content with leadership development and workforce development opportunities.
Behavioral: Forging Hopeful Futures
Forging Hopeful Futures is a 12 session curriculum for youth ages 13-19 that uses strengths-based and healing-centered approaches to critically examine structural forces that perpetuate racial and gender injustice, develop leadership skills in promoting gender equitable relationship norms, non-violent practices, and upstander skills, and enhance economic justice through job skills and employment opportunities. Through 12 sessions (3 hours/session) over a 6 to 12 week period, Forging Hopeful Futures combines racial, gender, and economic justice content with leadership development and workforce development opportunities.

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
Change in recent violence perpetration at 3 months
Time Frame: At baseline and three months after program conclusion
The primary outcome will be past 3-month youth violence perpetration. This will be measured by self-report on 3 items adapted from the Youth Risk Behavior Surveillance Survey, using a past-3 month reporting interval: 1) physical fighting ("How many times were you in a physical fight?"), 2) threatening someone with a weapon ("How many times have you threatened someone with a weapon such as a gun, knife, or club?"), and 3) injuring someone with a weapon ("How many times have you injured someone with a weapon such as a gun, knife, or club?"). Each item will be assessed with 8 frequency response categories from 0 times to 12 or more times. A summary score will capture the past 3-month incidence of all 3 behaviors (possible range: 0- 21;lower score indicates better outcome)
At baseline and three months after program conclusion

Secondary Outcome Measures

Secondary Outcome Measures

In a clinical study's protocol, a planned outcome measure that is not as important as the primary outcome measure for evaluating the effect of an intervention but is still of interest. Most clinical studies have more than one secondary outcome measure.
Outcome Measure
Measure Description
Time Frame
Change in recent violence perpetration at 6 months
Time Frame: At baseline and six months after program conclusion
This will be measured using the same 3 items outlined in the primary outcome, but assessed as a change from baseline to 6 months after program conclusion. This includes self-report on 3 items adapted from the Youth Risk Behavior Surveillance Survey, using a past-3 month reporting interval: 1) physical fighting ("How many times were you in a physical fight?"), 2) threatening someone with a weapon ("How many times have you threatened someone with a weapon such as a gun, knife, or club?"), and 3) injuring someone with a weapon ("How many times have you injured someone with a weapon such as a gun, knife, or club?"). Each item will be assessed with 8 frequency response categories from 0 times to 12 or more times. A summary score will capture the past 3-month incidence of all 3 behaviors (possible range: 0- 21;lower score indicates better outcome)
At baseline and six months after program conclusion
Change in relationship abuse at 3 months
Time Frame: At baseline and three months after program conclusion
10 abusive behavior items, modified from Conflict Tactics Scale-2, assess for perpetration against dating partners or towards peers. Summary score of any recent use of violence in the past 3 months (physical, sexual and emotional relationship abuse) calculated as one point for each behavior then summed (possible range: 0-10; lower score indicates better outcome).
At baseline and three months after program conclusion
Change in sexual violence perpetration at 3 months
Time Frame: At baseline and three months after program conclusion
4 sexual violence perpetration items assess recent sexual violence perpetration (any/none). Summary score of any recent sexual violence perpetration in the past 3 months, calculated as one point for each behavior then summed (possible range: 0-4; lower score indicates better outcome).
At baseline and three months after program conclusion
Change in cyber dating abuse and peer abuse
Time Frame: At baseline and three months after program conclusion
8 items assess using technology to perpetrate abuse against a dating partner or peers. Summary score of any recent use of technology to perpetrate abuse against a dating partner or peers in the past 3 months, calculated as one point for each behavior then summed (possible range: 0-8; lower score indicates better outcome).
At baseline and three months after program conclusion
Change in bullying perpetration
Time Frame: At baseline and three months after program conclusion
6 items to indicate frequency of bullying perpetration on 4-point frequency scale. Mean score of any recent bullying perpetration in the past 3 months, calculated as a mean score across the 6 items (possible range: 0-3; lower score indicates better outcome).
At baseline and three months after program conclusion
Change in cyberbullying perpetration
Time Frame: At baseline and three months after program conclusion
4-item scale adapted from a cyberbullying perpetration scale, assessing perpetration frequency on a 4-point frequency scale. Mean score of recent cyberbullying perpetration in the past 3 months, calculated as a mean across the 4 items (possible range:0-3; lower score indicated better outcome).
At baseline and three months after program conclusion
Change in weapon carrying
Time Frame: At baseline and three months after program conclusion
1 item adapted from the Youth Risk Behavior Surveillance Survey asking about frequency of carrying a weapon in the past 30 days (measured on a 5-point frequency scale from 0 days to 6 or more days; possible range: 0-4; lower score indicates better outcome).
At baseline and three months after program conclusion
Change in homophobic teasing
Time Frame: At baseline and three months after program conclusion
5-item scale with participants reporting how often they have perpetrated listed behaviors in the past 3 months (each item measured on a 6-point frequency scale from 0 times to 7 or more times). Mean score of recent homophobic teasing, calculated as a mean across the 5 items (possible range: 0-5; lower score indicates better outcome).
At baseline and three months after program conclusion
Change in sexual harassment
Time Frame: At baseline and three months after program conclusion
5 items assess frequency of perpetrating sexual harassing behaviors in the past 3 months, assessing perpetration frequency on a 5-point frequency scale. Mean score of recent sexual harassment perpetration in the past 3 months, calculated as a mean across the 5 items (possible range:0-4; lower score indicated better outcome).
At baseline and three months after program conclusion

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
University of Pittsburgh

Collaborators

Collaborators

An organization other than the sponsor that provides support for a clinical study. This support may include activities related to funding, design, implementation, data analysis, or reporting.
Centers for Disease Control and Prevention
Population Council

Investigators

Investigators

A researcher involved in a clinical study. Related terms include site principal investigator, site sub-investigator, study chair, study director, and study principal investigator.
  • Principal Investigator: Alison Culyba, MD PhD MPH, University of Pittsburgh

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
July 10, 2023

Primary Completion (Actual)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
August 2, 2026

Study Completion (Actual)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
August 2, 2026

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
February 13, 2023

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
February 14, 2023

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
February 24, 2023

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
September 3, 2026

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
August 31, 2026

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
August 1, 2026

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • STUDY22080150
  • R01CE003502 (U.S. NIH Grant/Contract)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

IDP data will be made available only to selected researchers who apply for access. The application must document a legitimate public health use or research question for the data, and the applicant must sign a pledge to keep all data private and to make no attempt to identify individual subjects. Access can be requested for all of the individual participant data collected during the trial, after deidentification. We will use data standards that ensure all released data have appropriate documentation that describes the method of collection, what the data represent, and potential limitations for use. Along with restricted use of the IDP, we will make available a comprehensive data dictionary that details all data elements included in the dataset, and sources of validated instruments. This use of the data is consistent with the planned language of the voluntary consent for participation agreed and in accordance with IRB policy.

IPD Sharing Time Frame

We will adhere to data sharing timelines, including sharing data (restricted use) within 30 months after the end of data collection.

IPD Sharing Access Criteria

We will make the data available only to selected researchers who apply for access. The application must document a legitimate public health use or research question for the data, and the applicant must sign a pledge to keep all data private and to make no attempt to identify individual subjects. This use of the data is consistent with the planned language of the voluntary consent for participation agreed and in accordance with IRB policy.

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings